Affiliation:
1. Department of Chemistry, University College of Science, Tumkur University, Tumakuru-572103, India
Abstract
A series of isoquinoline containing novel azo Schiff base derivatives (3a-l) were synthesized and
characterized by FT-IR, NMR (1H NMR & 13C NMR) and mass spectral analysis. The synthesized
title compounds were evaluated for in vitro antitubercular activity against Mycobacterium tuberculosis
(MTB) H37Rv strain by microplate alamar blue assay (MABA) method. Among the synthesized
series of compounds, the compounds 3a, 3b, 3c and 3d were emerged as excellent antitubercular
agents. Compound 3b showed the lowest MIC value of 1.6 μg/mL with a potency equivalent to the
standards, isoniazid and ethambutol. Compounds 3a & 3c showed MIC value of 3.125 μg/mL, which
is equivalent to the activity of a reference standard pyrazinamide. Compound 3d showed significant
activity with MIC of 6.25 μg/mL and other compounds showed good to moderate activity ranging
from 12.5 to 50 μg/mL. The four potent components were further tested for in vitro cytotoxicity using
MTT assay against MCF-7 and HeLa cell lines to check the selectivity index. Among the tested series,
compound 3b possessed the highest cytotoxicity against both MCF-7 (IC50, 7.09 ± 0.41) and HeLa
(IC50, 9.04 ± 0.34) cell lines. Additionally, in silico molecular docking was performed to study its
binding interaction with Mycobacterium tuberculosis enoyl reductase (InhA) and drug-like features
were studied using Swiss ADME tool. PASS analysis of all the compounds showed greater Pa than Pi
value for the antituberculosis activity. The results suggested that the synthesized isoquinoline containing
azo Schiff base derivatives becomes promising for developing new drugs to treat tuberculosis.
Publisher
Asian Journal of Chemistry
Reference35 articles.
1. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
2. World Health Organization, Rapid communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis, Global Tuberculosis Report, Geneva (2022).
3. R. Johnson, E.M. Streicher, G.E. Louw, R.M. Warren, P.D. Van Helden and T.C. Victor, Curr. Issues Mol. Biol., 8, 97 (2006).
4. World Health Organization, Catalogue of Mutations in Mycobacterium tuberculosis Complex and their Association with Drug Resistance, Global Tuberculosis Report, Geneva (2021).
5. Synthesis and pharmacological activities of azo dye derivatives incorporating heterocyclic scaffolds: a review